Ask AI
Navigating the CKM axis module 2

CE / CME

Navigating the CKM Axis: Improving CKD and HF Outcomes With Novel and Emerging GMDT

European Learners: 0.50 EBAC® CE Credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: December 19, 2025

Expiration: December 18, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, 5 experts across cardiology, endocrinology, and nephrology discuss the CKM axis and why GDMT improves both cardiovascular and kidney outcomes when used timely and together in patients with CKM syndrome.

Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

A 72-year-old woman with heart failure with mildly reduced ejection fraction (HFmrEF; left ventricular ejection fraction 45%), type 2 diabetes (T2D), and chronic kidney disease (CKD) stage 3b/A3 is being considered for intensification of therapy to improve heart and kidney outcomes. The patient is on lisinopril and loop diuretics. Her BMI is 32 kg/m2, blood pressure is 128/78 mm Hg, serum potassium is 4.7 mmol/L, estimated glomerular filtration rate (eGFR) is 35 mL/min/1.73 m², urine–albumin-to-creatinine ratio (UACR) is 450 mg/g, and A1C is 7.1%. According to current heart failure (HF) and CKD guidelines, which combination would optimize cardiovascular–kidney–metabolic (CKM) outcomes while minimizing adverse effects at this time?

In a randomized, dose‑finding phase II trial of vicadrostat in patients with CKD on stable RAAS inhibitor therapy, what key result was observed regarding albuminuria?

How confident are you in prescribing multiple therapies for patients with CKM syndrome?

How many patients do you see each week with a CKM disorder?

Please describe your practice setting: